Antirhinovirus activity of purine nucleoside analogs. 1986

E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy

A wide variety of purine nucleoside (mainly tubercidin and adenosine) analogs, which had previously been shown to inhibit the replication of a broad spectrum of RNA viruses, were evaluated for their antirhinovirus activity in human diploid (WI-38) fibroblasts. Tubercidin, 5-(1-hydroxyethyl)tubercidin, 5-(2-buten-1-yl)tubercidin, toyocamycin, and sangivamycin emerged as the most potent inhibitors. These compounds inhibited the replication of rhinovirus types 1A, 1B, and 9 at an MIC well below 1 microgram/ml. However, these compounds proved cytotoxic for the uninfected host cells at concentrations which were only slightly higher (3- to 10-fold, on the average) than those required for inhibition of rhinovirus replication. The most selective inhibitor of rhinovirus replication was 3-deazaguanine, with a selectivity index of 50. None of the carbocyclic and acyclic analogs of adenosine tested exhibited a potent or selective antirhinovirus activity.

UI MeSH Term Description Entries
D011684 Purine Nucleosides Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES. Purine Nucleoside,Nucleoside, Purine,Nucleosides, Purine
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003588 Cytopathogenic Effect, Viral Visible morphologic changes in cells infected with viruses. It includes shutdown of cellular RNA and protein synthesis, cell fusion, release of lysosomal enzymes, changes in cell membrane permeability, diffuse changes in intracellular structures, presence of viral inclusion bodies, and chromosomal aberrations. It excludes malignant transformation, which is CELL TRANSFORMATION, VIRAL. Viral cytopathogenic effects provide a valuable method for identifying and classifying the infecting viruses. Cytopathic Effect, Viral,Viral Cytopathogenic Effect,Cytopathic Effects, Viral,Cytopathogenic Effects, Viral,Effect, Viral Cytopathic,Effect, Viral Cytopathogenic,Effects, Viral Cytopathic,Effects, Viral Cytopathogenic,Viral Cytopathic Effect,Viral Cytopathic Effects,Viral Cytopathogenic Effects
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012229 Rhinovirus A genus of PICORNAVIRIDAE inhabiting primarily the respiratory tract of mammalian hosts. It includes over 100 human serotypes associated with the COMMON COLD. Common Cold Virus,Coryza Viruses,Cold Virus, Common,Cold Viruses, Common,Common Cold Viruses,Coryza Virus,Rhinoviruses
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications

Related Publications

E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
January 1965, Cancer research,
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
January 2001, Cancer chemotherapy and biological response modifiers,
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
January 2015, Chemistry Central journal,
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
June 2000, Oncology (Williston Park, N.Y.),
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
January 1991, Pharmacology & therapeutics,
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
August 1975, Annals of the New York Academy of Sciences,
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
November 2006, Current opinion in oncology,
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
June 2000, Oncology (Williston Park, N.Y.),
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
December 2020, Analytica chimica acta,
E De Clercq, and R Bernaerts, and D E Bergstrom, and M J Robins, and J A Montgomery, and A Holy
December 2019, Molecules (Basel, Switzerland),
Copied contents to your clipboard!